RECRUITING

The Weight of Cardiovascular Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.

Official Title

The Weight of Cardiovascular Disease: A Prospective Pilot Study of Obese Adults With Cardiovascular Disease Evaluated in a Novel Cardiometabolic Clinic

Quick Facts

Study Start:2024-04-22
Study Completion:2025-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06053645

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * BMI ≥30 kg/m2
  2. * At least one of the following CVD: atrial fibrillation (AF), coronary artery disease (CAD), HFpEF (heart failure with preserved ejection fraction), HFrEF (heart failure with reduced ejection fraction), ACHD (adult congenital heart disease), or valvular heart disease
  3. * Patients evaluated in the Cardiometabolic clinic
  4. * Willingness to complete questionnaires/surveys
  5. * Ability to complete monthly self-assessments at home
  1. * BMI \<30 kg/m2
  2. * Pregnancy or lactating women
  3. * Hemodynamically unstable CVD
  4. * Active malignancy
  5. * Autoimmune or systemic inflammatory diseases
  6. * Severe renal or hepatic failure
  7. * Being considered unsafe to participate as determined by the study physician
  8. * Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic medications, or other medications as determined by the study NP or physician
  9. * Patients with active psychosis, mania, or substance use disorders

Contacts and Locations

Study Contact

Preventive/Vascular Research Team
CONTACT
(507) 538-7425
RSTCVRUPREVENT@mayo.edu
Kyla Lara-Breitinger, M.D.
CONTACT
(507) 284-4441
Lara.Kyla@mayo.edu

Principal Investigator

Kyla Lara-Breitinger, M.D.
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Kyla Lara-Breitinger, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-22
Study Completion Date2025-09

Study Record Updates

Study Start Date2024-04-22
Study Completion Date2025-09

Terms related to this study

Additional Relevant MeSH Terms

  • Cardiovascular Diseases
  • Obesity